** Animal diagnostics maker IDEXX Laboratories' IDXX.O shares down 1.2% at $406.41
** BofA Global Research cuts PT to $475 from $535 on vet visit declines
** The new PT represents a 30% upside to the stock's last close
** "IDXX's direct leverage to clinic visit volumes creates a tough setup given the weak readings through Q1 and April so far" - BofA
** Brokerage says vet visit trends "leave a little room for upside revisions"
** IDXX expects about a 2% decline in clinical visits for 2025 - co said on a Q4 conference call
** Eight of 14 brokerages rate the stock "buy" or higher, six "hold"; their median PT is $502.13 - LSEG
** Including session's move, IDXX down 1.5% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。